Skip to main content
. Author manuscript; available in PMC: 2017 Jul 19.
Published in final edited form as: J Allergy Clin Immunol Pract. 2014 Nov 6;2(6):658–663. doi: 10.1016/j.jaip.2014.09.011

Figure 2.

Figure 2

Prebronchodilator FEV0.5 and FEV1 values assessed longitudinally between 5 and 8 years of age demonstrating significant reductions in children with histories of recurrent (≥2) wheezing exacerbations treated with oral corticosteroids (OCS) compared with those seen in children with no wheezing, mild-to-moderate wheezing, or 1 severe wheezing exacerbation requiring OCSs. Adapted from O'Brian, et. al. JACI 128:4 pages 1162-1164, 2012